Edition:
United States

Mylan NV (MYL.OQ)

MYL.OQ on NASDAQ Stock Exchange Global Select Market

46.59USD
22 Jul 2016
Change (% chg)

$-0.27 (-0.58%)
Prev Close
$46.86
Open
$47.04
Day's High
$47.04
Day's Low
$46.10
Volume
770,702
Avg. Vol
1,608,334
52-wk High
$68.04
52-wk Low
$37.59

MYL.OQ

Chart for MYL.OQ

About

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment... (more)

Overall

Beta: 1.24
Market Cap(Mil.): $23,684.85
Shares Outstanding(Mil.): 508.37
Dividend: --
Yield (%): --

Financials

  MYL.OQ Industry Sector
P/E (TTM): 29.78 36.15 37.05
EPS (TTM): 1.56 -- --
ROI: 4.54 15.11 14.35
ROE: 8.32 16.17 15.56

BRIEF-Mylan and Biocon announce regulatory submission accepted for review by EMA

* Mylan and Biocon announce regulatory submission for proposed Biosimilar Pegfilgrastim accepted for review by European Medicines Agency Source text for Eikon: Further company coverage: (Bengaluru Newsroom; +1 646 223 8780)

Jul 21 2016

Mylan gets EU approval for Meda purchase, subject to conditions

BRUSSELS EU antitrust regulators said on Wednesday they had cleared generic drugmaker Mylan's planned cash-and-stock purchase of Sweden's Meda subject to it selling certain assets.

Jul 20 2016

Mylan gets EU approval for Meda purchase, subject to conditions

BRUSSELS, July 20 EU antitrust regulators said on Wednesday they had cleared generic drugmaker Mylan's planned cash-and-stock purchase of Sweden's Meda subject to it selling certain assets.

Jul 20 2016

BRIEF-Pulmatrix and Mylan collaborate for pilot pharmacokinetic clinical study

* Pulmatrix led pilot pharmacokinetic clinical study and supportive development work with collaborative support from Mylan

Jul 19 2016

Mylan to get EU green light for Swedish drugmaker deal -sources

U.S. generic drugmaker Mylan is expected to win conditional EU antitrust approval for its planned takeover of Swedish rival Meda AB after agreeing to shed some assets, two people familiar with the matter said on Friday.

Jul 15 2016

Exclusive: Mylan to get EU green light for Swedish drugmaker deal - sources

BRUSSELS U.S. generic drugmaker Mylan is expected to win conditional EU antitrust approval for its planned takeover of Swedish rival Meda AB after agreeing to shed some assets, two people familiar with the matter said on Friday.

Jul 15 2016

BRIEF-Mylan launches generic Temodar capsules

* U.S. Launch of Temozolomide capsules, 5 mg, 20 mg, 100 mg, 140 mg, 180 mg and 250 mg, which is a generic version of Merck's Temodar Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jul 11 2016

BRIEF-Mylan launches generic Fenoglide tablets

* u.s. Launch of fenofibrate tablets usp, 40 mg and 120 mg, which is a generic version of santarus's fenoglide

Jul 06 2016

EU mergers and takeovers (July 6)

BRUSSELS, July 6 The following are mergers under review by the European Commission and a brief guide to the EU merger process:

Jul 06 2016

Mylan offers EC concessions to get approval for $7.2 bln Meda buy

BRUSSELS, June 30 - U.S. generic drugmaker Mylan NV has offered concessions in a bid to allay concerns by EU competition regulators over its proposed $7.2-billion acquisition of Swedish rival Meda, the European Commission said on Thursday.

Jun 30 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : Stock Traders Daily
$20.00
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.